{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:47:30Z","timestamp":1787165250913,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Municipal Key Clinical Specialty","award":["shslczdzk03402"],"award-info":[{"award-number":["shslczdzk03402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00259-025-07316-w","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:42:21Z","timestamp":1746668541000},"page":"4477-4486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Yanfei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-281X","authenticated-orcid":false,"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"7316_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7316_CR2","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.","journal-title":"Nat Rev Dis Primers"},{"key":"7316_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21:529\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"7316_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W 3rd, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in Non-Small cell lung Cancer. Cancer Res. 2016;76:227\u201338.","journal-title":"Cancer Res"},{"key":"7316_CR5","unstructured":"TECENTRIQ \u00ae (Atezolizumab) injection, for intravenous use initial U.S. 2016. Reference ID:4748227.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s033s034s035s036s037s038lbl.pdf. Accessed 6 September 2021."},{"key":"7316_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai L, Xu A, Xu J. Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33\u201359.","journal-title":"Adv Exp Med Biol"},{"key":"7316_CR7","doi-asserted-by":"publisher","first-page":"668612","DOI":"10.3389\/fmed.2021.668612","volume":"8","author":"E Tejerina","year":"2021","unstructured":"Tejerina E, Garca Tobar L, Echeveste JI, de Andrea CE, Vigliar E, Lozano MD. PD-L1 in cytological samples: A review and a practical approach. Front Med (Lausanne). 2021;8:668612.","journal-title":"Front Med (Lausanne)"},{"key":"7316_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-020-00639-9","volume":"10","author":"X Wu","year":"2020","unstructured":"Wu X, Huang Y, Zhao Q, et al. PD-L1 expression correlation with metabolic parameters of FDG PET\/CT and clinicopathological characteristics in non-small cell lung cancer. EJNMMI Res. 2020;10:51.","journal-title":"EJNMMI Res"},{"key":"7316_CR9","first-page":"686","volume":"63","author":"J Smit","year":"2022","unstructured":"Smit J, Borm FJ, Niemeijer AN, et al. PD-L1 PET\/CT imaging with radiolabeled durvalumab in patients with Advanced-Stage Non-Small cell lung Cancer. J Nucl Med. 2022;63:686\u201393.","journal-title":"J Nucl Med"},{"key":"7316_CR10","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","volume":"9","author":"AN Niemeijer","year":"2018","unstructured":"Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664.","journal-title":"Nat Commun"},{"key":"7316_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc882","volume":"2","author":"SS Gambhir","year":"2002","unstructured":"Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683\u201393.","journal-title":"Nat Rev Cancer"},{"key":"7316_CR12","doi-asserted-by":"crossref","unstructured":"Mu W, Jiang L, Shi Y et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET\/CT images. J Immunother Cancer 2021;9.","DOI":"10.1136\/jitc-2020-002118"},{"key":"7316_CR13","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1038\/s41467-020-19116-x","volume":"11","author":"W Mu","year":"2020","unstructured":"Mu W, Jiang L, Zhang J, et al. Non-invasive decision support for NSCLC treatment using PET\/CT radiomics. Nat Commun. 2020;11:5228.","journal-title":"Nat Commun"},{"key":"7316_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4103\/jcrt.jcrt_88_23","volume":"19","author":"Y Chen","year":"2023","unstructured":"Chen Y, Guo Y, Liu Z, Hu X, Hu M. An overview of current advances of PD-L1 targeting immuno-imaging in cancers. J Cancer Res Ther. 2023;19:866\u201375.","journal-title":"J Cancer Res Ther"},{"key":"7316_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line treatment of PD-L1-Selected patients with NSCLC. N Engl J Med. 2020;383:1328\u201339.","journal-title":"N Engl J Med"},{"key":"7316_CR16","doi-asserted-by":"publisher","first-page":"1958590","DOI":"10.1080\/2162402X.2021.1958590","volume":"10","author":"H Jin","year":"2021","unstructured":"Jin H, D\u2019Urso V, Neuteboom B, et al. Avelumab internalization by human Circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. Oncoimmunology. 2021;10:1958590.","journal-title":"Oncoimmunology"},{"key":"7316_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.121.262045","volume":"63","author":"X Zhou","year":"2022","unstructured":"Zhou X, Jiang J, Yang X, et al. First-in-Humans evaluation of a PD-L1-Binding peptide PET Radiotracer in Non-Small cell lung Cancer patients. J Nucl Med. 2022;63:536\u201342.","journal-title":"J Nucl Med"},{"key":"7316_CR18","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1007\/s00259-022-05876-9","volume":"49","author":"M Zhou","year":"2022","unstructured":"Zhou M, Wang X, Chen B, et al. Preclinical and first-in-human evaluation of (18)F-labeled D-peptide antagonist for PD-L1 status imaging with PET. Eur J Nucl Med Mol Imaging. 2022;49:4312\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7316_CR19","doi-asserted-by":"crossref","unstructured":"Wu Y, Xu D, Gu Y et al. Assessment of PD-L1 expression in Non-Small cell lung cancers using [(68)Ga]Ga-DOTA-WL12 PET\/CT. Small Methods 2024:e2400358.","DOI":"10.1002\/smtd.202400358"},{"key":"7316_CR20","doi-asserted-by":"crossref","unstructured":"Zhang Y, Cao M, Wu Y et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [(68)Ga]Ga-NOTA-RW102 in patients with lung cancers. J Immunother Cancer 2024;12.","DOI":"10.1136\/jitc-2024-008794"},{"key":"7316_CR21","doi-asserted-by":"publisher","first-page":"924223","DOI":"10.3389\/fonc.2022.924223","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu J, Deng H, Zhong H, Wang T, Rao Z, Wang Y, et al. Comparison of (68)Ga-FAPI and (18)F-FDG PET\/CT in the evaluation of patients with newly diagnosed Non-Small cell lung Cancer. Front Oncol. 2022;12:924223. https:\/\/doi.org\/10.3389\/fonc.2022.924223.","journal-title":"Front Oncol"},{"key":"7316_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. Non-Small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:504\u201335.","journal-title":"J Natl Compr Canc Netw"},{"key":"7316_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1039\/D0CB00070A","volume":"1","author":"K Hu","year":"2020","unstructured":"Hu K, Xie L, Hanyu M, et al. Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint. RSC Chem Biol. 2020;1:214\u201324.","journal-title":"RSC Chem Biol"},{"key":"7316_CR24","doi-asserted-by":"publisher","first-page":"14414","DOI":"10.1002\/anie.201807298","volume":"57","author":"AFB R\u00e4der","year":"2018","unstructured":"R\u00e4der AFB, Weinm\u00fcller M, Reichart F, et al. Orally active peptides: is there a magic bullet?? Angew Chem Int Ed Engl. 2018;57:14414\u201338.","journal-title":"Angew Chem Int Ed Engl"},{"key":"7316_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1039\/D1CB00023C","volume":"2","author":"TJ Harmand","year":"2021","unstructured":"Harmand TJ, Islam A, Pishesha N, Ploegh HL. Nanobodies as in vivo, non-invasive, imaging agents. RSC Chem Biol. 2021;2:685\u2013701.","journal-title":"RSC Chem Biol"},{"key":"7316_CR26","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.7150\/jca.38689","volume":"11","author":"H Jiang","year":"2020","unstructured":"Jiang H, Zhang R, Jiang H, Zhang M, Guo W, Zhang J, et al. Retrospective analysis of the prognostic value of PD-L1 expression and (18)F-FDG PET\/CT metabolic parameters in colorectal cancer. J Cancer. 2020;11:2864\u201373. https:\/\/doi.org\/10.7150\/jca.38689.","journal-title":"J Cancer"},{"key":"7316_CR27","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1002\/cam4.1215","volume":"6","author":"K Takada","year":"2017","unstructured":"Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography. Cancer Med. 2017;6:2552\u201361. https:\/\/doi.org\/10.1002\/cam4.1215.","journal-title":"Cancer Med"},{"key":"7316_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12149-020-01571-7","volume":"35","author":"YJ Choi","year":"2021","unstructured":"Choi YJ, Jo K, Hwang SH, Jeong Y, Lee JY, Kim S, et al. Association between PD-L1 expression and (18)F-FDG uptake in ovarian cancer. Ann Nucl Med. 2021;35:415\u201320. https:\/\/doi.org\/10.1007\/s12149-020-01571-7.","journal-title":"Ann Nucl Med"},{"key":"7316_CR29","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861\u201371.","journal-title":"Mol Cancer Ther"},{"key":"7316_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cmmi.408","volume":"6","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011;6:85\u201392.","journal-title":"Contrast Media Mol Imaging"},{"key":"7316_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.7150\/thno.8156","volume":"4","author":"M D\u2019Huyvetter","year":"2014","unstructured":"D\u2019Huyvetter M, Vincke C, Xavier C, et al. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4:708\u201320.","journal-title":"Theranostics"},{"key":"7316_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cmmi.408","volume":"6","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011;6:85\u201392. https:\/\/doi.org\/10.1002\/cmmi.408.","journal-title":"Contrast Media Mol Imaging"},{"key":"7316_CR33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","volume":"56","author":"KL Chatalic","year":"2015","unstructured":"Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, et al. A novel \u00b9\u00b9\u00b9In-Labeled Anti-Prostate-Specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate Cancer. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2015;56:1094\u20139. https:\/\/doi.org\/10.2967\/jnumed.115.156729.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07316-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07316-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07316-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:45Z","timestamp":1759394205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07316-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7316"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07316-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the ethics committee of Huashan Hospital Institutional Review Board (HIRB), Fudan University, China. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ehical approval"}},{"value":"Patients signed informed consent regarding the publication of their data and photographs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involoving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants or legal guardians included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors Fang Xie and Weijun Wei are editors of the Journal, and the rest have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Confict of interest"}}]}}